Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma
2상
완료
NCT00183820
| 대상 질환 | Testicular Cancer, Germ Cell Neoplasm |
|---|
| 임상 단계 | 2상 |
|---|
| 스폰서 | University of Southern California |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 30 명 |
|---|
| 중재(약물) | paclitaxel, gemcitabine, and oxaliplatin |
|---|
| 시작일 | 2004년 11월 |
|---|
| 완료일 | 2015년 12월 |
|---|
| 결과 공개일 | 2026년 7월 1일 |
|---|
요약
This is a study for patients with advanced testicular cancer. This research study involves treatment with oxaliplatin, paclitaxel, and gemcitabine, which is an investigational chemotherapy combination. This study is for patients who have not responded to standard cisplatin-containing chemotherapy or the cancer has returned after such treatment. This research is being done to assess the effectiveness of the proposed combination of medications for this type of cancer.
Tumor Response
From start of study drug until the date of first documented progression or date of death from any cause, whichever came first, assessed every 6 weeks, through study completion, up to 9 years · Participants
| Paclitaxel, Gemcitabine, and Oxaliplatin | 2 Participants |
|---|
| Paclitaxel, Gemcitabine, and Oxaliplatin | 7 Participants |
|---|
| Paclitaxel, Gemcitabine, and Oxaliplatin | 15 Participants |
|---|
| Paclitaxel, Gemcitabine, and Oxaliplatin | 5 Participants |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.